CANF Stock Analysis: Buy, Sell, or Hold?
CANF - Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares
$3.07
-0.02 (-0.65%)
▼
5d:
-6.69%
30d:
-49.0%
90d:
+1435.0%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Apr 13, 2026
10d
Get Alerted When CANF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CANF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CANF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CANF is currently trading at $3.07, which is considered oversold relative to its 30-day fair value range of $3.13 to $4.67.
Technical Outlook: Technically, CANF is in a strong uptrend. Immediate support is located at $2.95, while resistance sits at $3.42.
Market Sentiment: CANF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.50 (+13.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CANF is in a strong uptrend. Immediate support is located at $2.95, while resistance sits at $3.42.
Market Sentiment: CANF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.50 (+13.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.13 -
$4.67
Company Quality Score
46/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
50.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: Trading below Wall St target ($3.50)
- CAUTION: 5-day price weakness (-6.7%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$3.13 -
$4.67
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.95
Resistance Level
$3.42
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-77.25
Wall Street Target
$3.50
(+13.3%)
Revenue Growth (YoY)
-36.1%
Share & Embed Analysis
Last updated: April 02, 2026 4:56 PM ET
Data refreshes hourly during market hours. Next update: 5:56 PM
Data refreshes hourly during market hours. Next update: 5:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CANF showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 58 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 60 HOLD |
